Airway Reactivity
Conditions
Keywords
Airway Resistance, montelukast sodium, laryngeal mask airway
Brief summary
Supraglottic airway equipment used during anaesthesia application can lead to airway reactivity or even larynx spasm in sensitive children. Montelukast Sodium, used in asthma treatment, is a cysteinyl leukotriene Type 1 antagonist which reduces leukotriene C4, leukotriene D4 and leukotriene E4 synthesis. The use of Montelukast Sodium in airway reactivity is known to reduce the need for bronchodilator and corticosteroids.
Detailed description
The study will comprise 30 american society of anesthesiology (ASA) I-III patients, aged 4-8 years, undergoing inguinal hernia surgery. Patients will exclude if receiving asthma treatment, if they had upper respiratory tract infection in the last week and if the laryngeal mask airway (LMA) could not be placed at a single attempt. Patients will be separated into 3 groups as Group E (n=10) with high immunoglobulin E (IgE), Group C (n=10) with normal IgE and Group M (n=10) who were administered with 4mg peroral Montelukast Sodium, 10 days before surgery because of high IgE. With spontaneous breathing after anaesthesia induction, a classic LMA will be placed. Anaesthesia will be maintained with a mixture of 1.3 minimum alveolar concentration (MAC) sevoflurane 500%2 - N2O. At 5-minute intervals, oxygen saturation (sPO2), End-Tidal carbon dioxide, Heart Rate, tidal volume (VT), respiratory rate (f) and peak airway pressure (PAP) will be monitored and coughing, apnea, laryngospasm , bronchospasm, desaturation and need for steroids will be noted.
Interventions
DRUGmontelukast sodium
4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
Sponsors
Umraniye Education and Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
4 Years to 8 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients undergoing inguinal hernia surgery
Exclusion criteria
* If receiving asthma treatment, * If they had URTI in the last week and * If LMA could not be placed at a single attempt.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with bronchospasm as a Measure of airway reactivity | during the operation |
| Number of Participants with laryngospasm as a Measure of airway reactivity | during the operation |
| Number of Participants with apnea | during the operation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| amount of applied steroids | during the operation | steroids can prevent airway reactivity symptoms |
| peak airway pressures as a measurement of airway reactivity | during the operation | — |
Countries
Turkey (Türkiye)
Outcome results
None listed